Plasma Fractionation Global Market Outlook 2023-2032: Size And Growth Rate Analysis
The Business Research Company’s global market reports provide comprehensive analysis on the various markets in 27 industries across 60 geographies.
The global plasma fractionation market is poised for significant expansion, with its size projected to grow from $26.18 billion in 2022 to $28.61 billion in 2023, boasting a commendable compound annual growth rate (CAGR) of 9.3%. Looking ahead to 2027, the market is anticipated to reach $40.68 billion at a CAGR of 9.2%. At the heart of this growth is the surge in chronic diseases, conditions lasting a year or more that necessitate ongoing medical attention. Notable examples include heart disease, cancer, and diabetes. Treating patients with chronic diseases through plasma products not only reduces morbidity but also enhances the quality of life. This approach proves cost-effective, fostering an increased demand for plasma fractionation. The World Health Organization reports a staggering 57% rise in chronic disease prevalence by 2020, underscoring the critical role plasma fractionation plays in addressing global health challenges.
Market Stalwarts: Key Players Steering the Course
Leading the Charge
Major players shaping the landscape of the plasma fractionation market include industry stalwarts such as Baxter International Inc., Bio Products Laboratory, Biotest AG, CSL Limited, Grifols S.A, Kedrion S.p.A, LFB S. A., Octapharma AG, Sanquin Blood Supply Foundation, Takeda Pharmaceutical Company Limited, Chinese Biological Products Inc., Japan Blood Products Organization, Green Cross Corporation, and Intas Pharmaceuticals Ltd. These key players contribute significantly to the dynamic growth and evolution of the market.
Innovation in Focus: Technological Advancements Driving Market Dynamics
The plasma fractionation market is experiencing a paradigm shift driven by technological advancements. Major companies in the market are at the forefront of introducing cutting-edge technologies to sustain their positions. One notable example is the introduction of HYCON by GAE, a Germany-based company specializing in systems for the pharmaceutical sector. Launched in June 2021, HYCON stands as a fully automatic separator designed for one-touch production, facilitating the separation of blood plasma and plasma proteins in cleanroom applications. This innovative technology incorporates self-cleaning features, ensuring improved hygienic conditions, prevention of cross-contamination, and enhanced batch safety. As technological trends gain traction, they continue to redefine the landscape of plasma fractionation.
Segmentation Spotlight: Navigating the Diverse Market Dynamics
Comprehensive Market Segmentation
The plasma fractionation market is strategically segmented to provide a comprehensive understanding of its diverse dynamics:
- By Product:
- Coagulation Factors
- Protease Inhibitors
- By Application:
- Critical Care
- By End User:
- Hospitals and Clinics
- Clinical Research Laboratories
- Academic Institutes
Global Dynamics: Regional Impacts
While North America emerged as the largest region in the plasma fractionation market in 2022, the spotlight is on Asia-Pacific as the fastest-growing region in the forecast period. This dynamic regional landscape highlights the global nature of the plasma fractionation market, with different regions contributing significantly to its vibrancy and growth.
View More On The Plasma Fractionation Market Report 2023 – https://www.thebusinessresearchcompany.com/report/plasma-fractionation-global-market-report
RequestA Sample Of The Global Plasma Fractionation Market Report 2023:
The Plasma Fractionation Global Market Report 2023 provides a comprehensive overview on the plasma fractionation market size, trends and drivers, opportunities, strategies, and companies analysis. Through our reports businesses can effectively analyze data and frame well-informed strategies
Follow us on:
Global Market Model:https://www.thebusinessresearchcompany.com/global-market-model